Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 12, 2012, Pages 1315-1325.e4

  Pola, Suresh ^a   Patel, Derek ^a   Ramamoorthy, Sonia ^a   McLemore, Elisabeth ^a   Fahmy, Marianne ^a   Rivera Nieves, Jesus ^a,b   Chang, John T ^a,b   Evans, Elisabeth ^a   Docherty, Michael ^a   Talamini, Mark ^a   Sandborn, William J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

CMV; Colectomy; CT; IBD; Inflammatory Bowel Disease; Inpatient Management; PCR; TNF; TPMT; UC; Ulcerative Colitis

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; NARCOTIC AGENT; PARACETAMOL; PREDNISONE; TRAMADOL; VALGANCICLOVIR; VANCOMYCIN;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ABDOMINAL TENDERNESS; ADHESION; ANALGESIA; ANTIVIRAL THERAPY; APPENDICITIS; BLOATING; BLOOD CELL COUNT; CLOSTRIDIUM DIFFICILE INFECTION; COLON HEMORRHAGE; COLON PERFORATION; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DIVERTICULITIS; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; FECES INCONTINENCE; FEVER; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOVOLEMIA; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; MORTALITY; NAUSEA AND VOMITING; NUTRITION; PATIENT CARE; PROCTOCOLECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REVIEW; SALVAGE THERAPY; SEPSIS; SIGMOIDOSCOPY; TOXIC MEGACOLON; TREATMENT INDICATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

EID: 84869456003     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.07.006     Document Type: Review

References (109)

1. Edwards F.C., Truelove S.C. The course and prognosis of ulcerative colitis. Gut 1963, 4:299-315.
2. Dinesen L.C., Walsh A.J., Protic M.N., et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010, 4:431-437.
3. Kohn A., Fano V., Monterubbianesi R., et al. Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: a 10-year cohort study. Dig Liver Dis 2012, 44:369-374.
4. Turner D., Walsh C.M., Steinhart A.H., et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5:103-110.
5. Ananthakrishnan A.N., McGinley E.L., Binion D.G., et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg 2011, 15:267-276.
6. Bitton A., Buie D., Enns R., et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012, 107:179-194. author reply, 195.
7. Hanauer S.B. Inflammatory bowel disease. N Engl J Med 1996, 334:841-848.
8. Lichtiger S., Present D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990, 336:16-19.
9. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
10. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
11. Farmer R.G., Easley K.A., Rankin G.B. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993, 38:1137-1146.
12. Carbonnel F., Lavergne A., Lémann M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994, 39:1550-1557.
13. Ho G.T., Mowat C., Goddard C.J., et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004, 19:1079-1087.
14. Truelove S.C., Jewell D.P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974, 1:1067-1070.
15. Travis S.P., Farrant J.M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
16. Terheggen G., Lanyi B., Schanz S., et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy 2008, 40:656-663.
17. Alemayehu G., Järnerot G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol 1991, 86:187-190.
18. Navaneethan U., Parasa S., Venkatesh P.G., et al. Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. J Crohns Colitis 2011, 5:189-195.
19. Sandborn W.J. Therapeutic approaches to the treatment of ulcerative colitis. Inflammatory bowel disease. Translating basic science into clinical practice 2010, 415. Wiley-Blackwell, Hoboken, NJ. S. Targan, F. Shanahan, L. Karp (Eds.).
20. Sturgeon J.B., Bhatia P., Hermens D., et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology 1995, 108:1889-1893.
21. Kapur K.C., Williams G.T., Allison M.C. Mesalazine induced exacerbation of ulcerative colitis. Gut 1995, 37:838-839.
22. Gupta M.K., Pollack S., Hutchings J.J. Mesalamine induced symptom exacerbation of ulcerative colitis: case report and brief discussion. World J Gastrointest Pharmacol Ther 2010, 1:132-134.
23. Baron J.H., Connell A.M., Kanaghinis T.G., et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962, 2:441-443.
24. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978, 13:833-837.
25. Meyers S., Lerer P.K., Feuer E.J., et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987, 9:50-54.
26. Truelove S.C., Willoughby C.P., Lee E.G., et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978, 2:1086-1088.
27. Järnerot G., Rolny P., Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985, 89:1005-1013.
28. Gustavsson A., Halfvarson J., Magnuson A., et al. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007, 102:2513-2519.
29. Relling M.V., Gardner E.E., Sandborn W.J., et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011, 89:387-391.
30. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
31. Kornbluth A., Lichtiger S., Present D., et al. Long-term results of oral cyclosporin in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial. Gastroenterology 1994, 106:A714.
32. Svanoni F., Bonassi U., Bagnolo F., et al. Effectiveness of cyclosporine A (CsA) in the treatment of active refractory ulcerative colitis (UC). Gastroenterology 1998, 1998:A1096.
33. D'Haens G., Lemmens L., Geboes K., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120:1323-1329.
34. Laharie D., Bourreille A., Branche J., et al. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Gastroenterology 2011, 140:S112.
35. Pham C.Q., Efros C.B., Berardi R.R. Cyclosporine for severe ulcerative colitis. Ann Pharmacother 2006, 40:96-101.
36. Cohen R.D., Stein R., Hanauer S.B. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999, 94:1587-1592.
37. Arts J., D'Haens G., Zeegers M., et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004, 10:73-78.
38. Campbell S., Travis S., Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005, 17:79-84.
39. Moskovitz D.N., Van Assche G., Maenhout B., et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:760-765.
40. Actis G.C., Fadda M., David E., et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007, 7:13.
41. Van Assche G., D'Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025-1031.
42. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83-88.
43. Järnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
44. Armuzzi A., De Pascalis B., Lupascu A., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004, 8:231-233.
45. Ochsenkühn T., Sackmann M., Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004, 16:1167-1171.
46. Panaccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: UC SUCCESS trial (abstract 835). Gastroenterology 2011, 140:S134.
47. Selvasekar C.R., Cima R.R., Larson D.W., et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007, 204:956-962. discussion, 962-963.
48. Mor I.J., Vogel J.D., da Luz Moreira A., et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008, 51:1202-1207. discussion, 1207-1210.
49. Yang Z., Wu Q., Wu K., et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010, 31:486-492.
50. Kunitake H., Hodin R., Shellito P.C., et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008, 12:1730-1736. discussion, 1736-1737.
51. Ferrante M., D'Hoore A., Vermeire S., et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009, 15:1062-1070.
52. Coquet-Reinier B., Berdah S.V., Grimaud J.C., et al. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc 2010, 24:1866-1871.
53. Gainsbury M.L., Chu D.I., Howard L.A., et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg 2011, 15:397-403.
54. Bregnbak D., Mortensen C., Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis 2012, 6:281-286.
55. Maser E.A., Deconda D., Lichtiger S., et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008, 6:1112-1116.
56. Leblanc S., Allez M., Seksik P., et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011, 106:771-777.
57. Turner D., Mack D., Leleiko N., et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010, 138:2282-2291.
58. Lindgren S.C., Flood L.M., Kilander A.F., et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998, 10:831-835.
59. Aceituno M., García-Planella E., Heredia C., et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008, 14:347-352.
60. Grucela A., Steinhagen R.M. Current surgical management of ulcerative colitis. Mt Sinai J Med 2009, 76:606-612.
61. Cohen J.L., Strong S.A., Hyman N.H., et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005, 48:1997-2009.
62. Goligher J.C., de Dombal F.T., Graham N.G., et al. Early surgery in the management of severe ulcerative colitis. Br Med J 1967, 3:193-195.
63. Goligher J.C., Hoffman D.C., de Dombal F.T. Surgical treatment of severe attacks of ulcerative colitis, with special reference to the advantages of early operation. Br Med J 1970, 4:703-706.
64. Roberts S.E., Williams J.G., Yeates D., et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007, 335:1033.
65. de Silva S., Ma C., Proulx M.C., et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:972-980.
66. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
67. Nguyen G.C., Kaplan G.G., Harris M.L., et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:1443-1450.
68. Kaneko T., Matsuda R., Taguri M., et al. Clostridium difficile infection in patients with ulcerative colitis: investigations of risk factors and efficacy of antibiotics for steroid refractory patients. Clin Res Hepatol Gastroenterol 2011, 35:315-320.
69. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
70. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
71. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
72. Issa M., Weber L.R., Skaros S., et al. Decreasing rates of colectomy despite high rates of hospitalization in Clostridium difficile infected IBD patients: a tertiary referral center experience. Gastroenterology 2007, 132:A663.
73. Chiplunker A., Ananthakrishnan A.N., Beaulieu D.B., et al. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009, 136(Suppl 1):S1145.
74. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
75. Kandiel A., Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006, 101:2857-2865.
76. Lawlor G., Moss A.C. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. Inflamm Bowel Dis 2010, 16:1620-1627.
77. Maconi G., Colombo E., Zerbi P., et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis 2005, 37:418-423.
78. Cottone M., Pietrosi G., Martorana G., et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001, 96:773-775.
79. Criscuoli V., Casà A., Orlando A., et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis 2004, 36:818-820.
80. Domènech E., Vega R., Ojanguren I., et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008, 14:1373-1379.
81. Orvar K., Murray J., Carmen G., et al. Cytomegalovirus infection associated with onset of inflammatory bowel disease. Dig Dis Sci 1993, 38:2307-2310.
82. Pereyra F., Rubin R.H. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004, 17:357-361.
83. Lavagna A., Bergallo M., Daperno M., et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007, 13:896-902.
84. Lévêque N., Brixi-Benmansour H., Reig T., et al. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. J Med Virol 2010, 82:1694-1700.
85. Yoshino T., Nakase H., Ueno S., et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 2007, 13:1516-1521.
86. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee. Am J Gastroenterol 2010, 105:501-523. Practice Parameters Committee of the American College of Gastroenterology, quiz, 524.
87. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
88. Sands B.E. Fulminant colitis. J Gastrointest Surg 2008, 12:2157-2159.
89. Gan S.I., Beck P.L. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003, 98:2363-2371.
90. Jalan K.N., Sircus W., Card W.I., et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 1969, 57:68-82.
91. Latella G., Vernia P., Viscido A., et al. GI distension in severe ulcerative colitis. Am J Gastroenterol 2002, 97:1169-1175.
92. Sheth S.G., LaMont J.T. Toxic megacolon. Lancet 1998, 351:509-513.
93. Imbriaco M., Balthazar E.J. Toxic megacolon: role of CT in evaluation and detection of complications. Clin Imaging 2001, 25:349-354.
94. Autenrieth D.M., Baumgart D.C. Toxic megacolon. Inflamm Bowel Dis 2012, 18:584-591.
95. Panos M.Z., Wood M.J., Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 1993, 34:1726-1727.
96. Present D.H., Wolfson D., Gelernt I.M., et al. Medical decompression of toxic megacolon by "rolling". A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol 1988, 10:485-490.
97. Katzka I., Katz S., Morris E. Management of toxic megacolon: the significance of early recognition in medical management. J Clin Gastroenterol 1979, 1:307-311.
98. D'Amico C., Vitale A., Angriman I., et al. Early surgery for the treatment of toxic megacolon. Digestion 2005, 72:146-149.
99. Long M.D., Barnes E.L., Herfarth H.H., et al. Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm Bowel Dis 2012, 18:869-876.
100. Lian L., Fazio V.W., Hammel J., et al. Impact of narcotic use on the requirement for colectomy in inpatients with ulcerative colitis. Dis Colon Rectum 2010, 53:1295-1300.
101. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
102. Dickinson R.J., Ashton M.G., Axon A.T., et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980, 79:1199-1204.
103. McIntyre P.B., Powell-Tuck J., Wood S.R., et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986, 27:481-485.
104. Nguyen G.C., Munsell M., Harris M.L. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008, 14:1105-1111.
105. Nisar P.J., Appau K.A., Remzi F.H., et al. Preoperative hypoalbuminemia is associated with adverse outcomes after ileoanal pouch surgery. Inflamm Bowel Dis 2012, 18:1034-1041.
106. Hatoum O.A., Binion D.G. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005, 11:304-313.
107. Grainge M.J., West J., Card T.R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010, 375:657-663.
108. Nguyen G.C., Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:2272-2280.
109. Murthy S.K., Nguyen G.C. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011, 106:713-718.